

CITATION REPORT

List of articles citing

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

DOI: 10.2165/00003088-200038010-00003
Clinical Pharmacokinetics, 2000, 38, 41-57.

Source: <https://exaly.com/paper-pdf/32269900/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
665	Cytochrome P450 3. Clinically Significant Drug Interactions. 2000 , 30, 146-149		5
664	Organ transplantation in the HIV-infected patient. 2000 , 5, 217-223		4
663	Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. 2000 , 12 Suppl 1, 30-44		73
662	Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin-ergotamine drug interaction. 2000 , 30, 635-6		5
661	Does P-glycoprotein play a role in anticancer drug pharmacokinetics?. 2000 , 3, 357-363		34
660	High-throughput approaches to the quantitative analysis of ketoconazole, a potent inhibitor of cytochrome P450 3A4, in human plasma. 2000 , 14, 2282-93		44
659	Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. 2001 , 2, 401-15		54
658	Role of transport proteins in drug absorption, distribution and excretion. 2001 , 31, 469-97		390
657	What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?. 2001 , 24, 75-85		32
656	Pharmacokinetic interactions of antimalarial agents. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 343-73	6.2	93
655	Pharmacokinetic considerations in the treatment of inflammatory bowel disease. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 723-51	6.2	97
654	Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 833-68	6.2	96
653	Role of P-Glycoprotein and Organic Anion Transporting Polypeptides in Drug Absorption and Distribution. 2001 , 21, 587-596		13
652	Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. 2001 , 79, 220-226		20
651	Drug Interactions between Psychoactive Agents and Antiepileptic Agents. 2001 , 2, 92-105		1
650	Sildenafil citrate: a therapeutic update. 2001 , 23, 2-23		65
649	Solid organ transplantation in HIV-infected individuals: obstacles and opportunities. 2001 , 33, 1310-4		18

648	Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. 2001 , 58, 589-93	14
647	Clinically significant drug interactions with agents specific for migraine attacks. 2001 , 15, 105-18	38
646	Delusion of Worm Infestation Associated with Clarithromycin in a Patient on Peritoneal Dialysis. 2001 , 21, 415-416	5
645	Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. 2001 , 21, 603-7	73
644	Drug interactions. 2001 , 14, 411-6	12
643	Development of parkinsonian symptoms after discontinuation of carbamazepine in patients concurrently treated with risperidone: two case reports. 2001 , 24, 358-60	7
642	Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. 2001 , 24, 1263-6	17
641	CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. 2001 , 21, 398-407	61
640	Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. 2001 , 103, E119-20; author reply E119-20	2
639	Ketoconazole et itraconazole: interactions pharmacocinétiques. 2001 , 2001, 57-62	
638	Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism. 2001 , 753, 395-400	12
637	Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. 2001 , 15, 851-5	20
636	Review article: over-the-counter drugs and the gastrointestinal tract. 2001 , 15, 1263-70	9
635	Carbamazepine is not a substrate for P-glycoprotein. 2001 , 51, 345-9	111
634	In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. 2001 , 144, 316-20	40
633	Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. 2001 , 52, 399-407	14
632	Enantiomeric drug development: issues, considerations, and regulatory requirements. 2001 , 90, 1205-15	49
631	Forbidden fruit. 2001 , 7, 29-30	10

630	Drugs and cardiotoxicity in HIV and AIDS. 2001 , 946, 179-99	49
629	Possible interaction of zopiclone and nefazodone. 2001 , 35, 1378-80	9
628	Fluconazole-induced torsade de pointes. 2001 , 35, 432-4	40
627	Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. 2001 , 41, 85-91	88
626	Noncardiac drugs and QTc interval prolongation: an often unrecognized risk factor for adverse cardiovascular outcomes. 2002 , 11, 197-202	0
625	Miscellaneous antibacterial drugs. 2002 , 287-330	
624	Statins: balancing benefits, efficacy and safety. 2002 , 3, 469-77	9
623	Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. 2002 , 30, 63-8	51
622	Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. 2002 , 30, 757-62	32
621	Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. 2002 , 34, 751-90	17
620	The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. 2002 , 30, 336-43	89
619	The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. 2002 , 95, 667-73, table of contents	8
618	Antiepileptic-antipsychotic drug interactions: a critical review of the evidence. 2002 , 25, 280-9	18
617	Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature. 2002 , 3, 143-8	19
616	The Influence of Parecoxib, a Parenteral Cyclooxygenase-2 Specific Inhibitor, on the Pharmacokinetics and Clinical Effects of Midazolam. 2002 , 95, 667-673	26
615	Carbamazepine-risperidone interactions in patients with epilepsy. 2002 , 25, 97-100	15
614	Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. 2002 , 74, 1136-41	20
613	Metabolic extraction of nifedipine during absorption from the rat small intestine. 2002 , 17, 546-53	23

612	Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. 2002 , 8, 293-308		61
611	Clinically significant interactions with drugs used in the treatment of tuberculosis. 2002 , 25, 111-33		68
610	Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 343-70	6.2	305
609	Mechanisms of clinically relevant drug interactions associated with tacrolimus. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 813-51	6.2	217
608	Pharmacokinetics of Gepirone in Subjects with Normal Renal Function and in Patients with Chronic Renal Dysfunction. 2002 , 22, 513-522		1
607	Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. 2002 , 42, 222-8		40
606	Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. 2002 , 19, 25-42		48
605	Hyperlipidemia and graft loss. 2002 , 34, 2423-5		9
604	Factors contributing to carbamazepine-macrolide interactions. 2002 , 45, 291-8		19
603	Effects of H(2)-receptor antagonists on dapsone-induced methaemoglobinaemia in rats. 2002 , 45, 269-73		8
602	Use of complementary and alternative medications by surgical patients. 2002 , 17, 170-7		22
601	Interacciones relevantes de los fármacos metabolizados por el sistema P-450. 2002 , 9, 432-439		
600	[Ergotism in a patient treated with ritonavir and ergotamine]. 2002 , 119, 558-9		2
599	Limited induction of torsade de pointes by terikalant and erythromycin in an in vivo model. 2002 , 449, 143-53		19
598	Cytochromes P450 and experimental models of drug metabolism. 2002 , 6, 189-98		217
597	Isolation and structural elucidation of degradation products of alprazolam: photostability studies of alprazolam tablets. 2002 , 91, 1274-86		25
596	Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. 2002 , 23, 361-7		25
595	In vitro tests for predicting drug-drug interactions: the need for validated procedures. 2002 , 91, 209-17		27

594	The significance of QT interval in drug development. 2002 , 54, 188-202	170
593	Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. 2002 , 14, 178-88	25
592	Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry. 2002 , 35, 99-103	71
591	Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen. 2002 , 44, 194-5	45
590	CYP3A4 is a human microsomal vitamin D 25-hydroxylase. 2004 , 19, 680-8	113
589	Diagnosis and Treatment of Nonconvulsive Status Epilepticus in an Intensive Care Unit Setting. 2003 , 5, 93-110	21
588	Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. 2003 , 59, 23-8	22
587	Clinical relevance and management of drug-related QT interval prolongation. 2003 , 23, 881-908	73
586	Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. 2003 , 65, 109-20	12
585	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. 2003 , 65, 1853-65	5
584	Pharmacology of antineoplastic agents in older cancer patients. 2003 , 46, 101-14	36
583	Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6beta-hydroxycortisol in routine practice. For CYP 3A4 activity evaluation in basal conditions and after grapefruit juice intake. 2003 , 793, 357-66	14
582	Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam. 2003 , 55, 382-8	11
581	The effect of ketoconazole and diltiazem on oestrogen metabolism in postmenopausal women after single dose oestradiol treatment. 2003 , 56, 334-6	1
580	The effects of fruit juices on drug disposition: a new model for drug interactions. 2003 , 33 Suppl 2, 10-6	89
579	Pharmacodynamics and clinical use of anti-HIV drugs. 2003 , 17, 651-74	4
578	Oral antifungal drug interactions: a mechanistic approach to understanding their cause. 2003 , 21, 543-63, viii	8
577	Rhabdomyolysis from Cytochrome P-450 Interaction of Ketoconazole and Simvastatin in Prostate Cancer. 2003 , 169, 613-613	12

576	Ergotism associated with HIV antiviral protease inhibitor therapy. 2003 , 37, 676-8		30
575	Interactions of herbs with cytochrome P450. 2003 , 35, 35-98		320
574	Cardiovascular safety of sildenafil. 2003 , 26, 453-60		14
573	Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives. 2003 , 26, 707-20		34
572	Drug interactions between antiretroviral drugs and comedicated agents. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 223-82	6.2	106
571	Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 793-817	6.2	38
570	Pharmacokinetic interactions with rifampicin : clinical relevance. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 819-820	6.2	473
569	Factors affecting the clinical development of cytochrome p450 3A substrates. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 969-84	6.2	44
568	Dietary effects on drug metabolism and transport. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 1071-88	6.2	156
567	Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 1179-91	6.2	12
566	Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. 2003 , 22, 89-99		59
565	Review of the pharmacokinetics, interactions and adverse reactions of cyclosporine in people, dogs and cats. 2003 , 152, 739-48		46
564	Therapeutic monitoring of sirolimus: its contribution to optimal prescription. 2003 , 35, 157S-161S		27
563	QTc interval prolongation associated with intravenous methadone. 2003 , 105, 499-506		166
562	Clinically important drug interactions with intravenous anaesthetics in older patients. 2003 , 20, 969-80		17
561	Pharmacological factors influencing anticancer drug selection in the elderly. 2003 , 20, 737-59		31
560	Antidepressant-induced hepatotoxicity. 2003 , 2, 249-62		63
559	Clinically important drug interactions with zopiclone, zolpidem and zaleplon. 2003 , 17, 513-32		71

558	Early factors in successful anti-HIV treatment. 2003 , 2, 10-20	6
557	Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. 2003 , 304, 596-602	38
556	The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. 2003 , 12, 401-12	15
555	Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. 2003 , 348, 2175-85	763
554	Symptomatic hypotension with venlafaxine-benzodiazepine interaction. 2003 , 7, 273-6	0
553	Irreversible coma, ergotamine, and ritonavir. 2003 , 37, e72-3	6
552	Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. 2003 , 18, 128-38	38
551	Gender, ethnicity and genetics in cardiovascular disease: part 1: Basic principles. 2003 , 5, 129-43	15
550	Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. 2003 , 17, 851-9	75
549	Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. 2003 , 17, 2603-14	140
548	Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction. 2003 , 37, 202-5	15
547	Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. 2004 , 10, 2336-43	146
546	Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. 2004 , 32, 1146-53	78
545	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. 2004 , 9, 217-21	39
544	Drug interactions in dentistry: the importance of knowing your CYPs. 2004 , 135, 298-311	49
543	Sublingual sildenafil in the treatment of erectile dysfunction: faster onset of action with less dose. 2004 , 11, 989-92	17
542	Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. 2004 , 497, 223-31	10
541	Effect of cytochrome P450 inhibitors (diethyl dithiocarbamate, ketoconazole and grapefruit juice) on the pharmacokinetics of all-trans-retinoic acid. 2004 , 59, 697-702	5

540	An aminomethylpyrimidine DPP-IV inhibitor with improved properties. 2004 , 14, 3575-8		37
539	A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. 2004 , 54, 377-84		6
538	Rifampicin reduces plasma concentrations of celiprolol. 2004 , 59, 819-24		17
537	Effects of growth hormone deficiency and rhGH replacement therapy on the 6beta-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children. 2004 , 60, 559-64		15
536	Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. 2004 , 60, 709-15		63
535	Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death. 2004 , 6, 379-84		26
534	Drug Interactions Among the Antiretrovirals. 2004 , 6, 159-162		13
533	The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. 2004 , 57, 441-7		76
532	The effects of methadone and its role in fatalities. 2004 , 19, 565-76		93
531	Re-evaluation of the relative potency of synthetic and natural alpha-tocopherol: experimental and clinical observations. 2004 , 15, 380-95		52
530	High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. 2004 , 805, 241-7		53
529	Severe bone marrow depression induced by an anticancer herb <i>Cantharanthus roseus</i> . 2004 , 42, 667-71		6
528	Fulvestrant: pharmacokinetics and pharmacology. 2004 , 90 Suppl 1, S7-10		81
527	Prevention and management of prostate cancer chemotherapy complications. 2004 , 31, 367-78		4
526	Deadly drug interactions in emergency medicine. 2004 , 22, 845-63		24
525	The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. 2004 , 44, 111-36		53
524	Comparative pharmacokinetics and pharmacodynamics of short-acting hypnotics: zaleplon, zolpidem and zopiclone. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 227-38	6.2	165
523	Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 33-56	6.2	26

522	QT prolongation with antimicrobial agents: understanding the significance. 2004 , 64, 1091-124	91
521	Interactions between grapefruit juice and cardiovascular drugs. 2004 , 4, 281-97	144
520	Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. 2004 , 24, 851-874	632
519	Update on clinically significant drug interactions in dermatology. 2004 , 51, E1-E4	2
518	Herbal bioactivation: the good, the bad and the ugly. 2004 , 74, 935-68	176
517	Cytochrome P450. 2004 , 542-543	0
516	Systemic Absorption of Amitriptyline and Buspirone after Oral and Transdermal Administration to Healthy Cats. 2004 , 18, 43-46	51
515	Natural products and adverse drug interactions. <i>Cmaj</i> , 2004 , 170, 1531-2	3.5 27
514	No clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240. 2004 , 44, 379-87	2
513	Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. 2004 , 44, 793-803	16
512	P glycoprotein in human immunodeficiency virus type 1 infection and therapy. 2004 , 48, 1073-81	60
511	Predicting pharmacokinetic herb-drug interactions. 2004 , 20, 143-58	26
510	Absorption and metabolic extraction of diltiazem from the perfused rat small intestine. 2004 , 19, 430-7	6
509	Paradoxical cyclosporine A requirements in pediatric renal transplants receiving high-dose steroids. 2005 , 45, 161-7	0
508	Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. 2005 , 15, 599-608	69
507	The pharmacokinetics and interactions of new antiepileptic drugs: an overview. 2005 , 27, 722-6	33
506	Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. 2005 , 45, 422-33	69
505	Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. 2005 , 45, 1187-97	23

504	Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. 2005 , 77, 170-7	158
503	Neuroleptics in headache. 2005 , 45, 358-71	32
502	Past, present, and future: a 7-year update of Viagra (sildenafil citrate). 2005 , 59, 680-91	61
501	Comparison of a combination of midazolam and diazepam and midazolam alone as oral premedication on preanesthetic and emergence condition in children. 2005 , 49, 698-701	25
500	Inhibitory effect of several fluoroquinolones on hepatic microsomal cytochrome P-450 1A activities in dogs. 2005 , 28, 553-7	28
499	Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report. 2005 , 43, 252-5	6
498	Synergistic interaction between hesperidin, a natural flavonoid, and diazepam. 2005 , 512, 189-98	53
497	Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. 2005 , 25, 42-51	18
496	Síndrome de QT largo adquirido en pacientes ingresados en UCI. 2005 , 29, 379-383	2
495	Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. 2005 , 26, 59-65	13
494	Food-drug interactions in the summary of product characteristics of proprietary medicinal products. 2005 , 61, 77-83	17
493	[Genetic polymorphism and drug interactions: their importance in the treatment of pain]. 2005 , 52, 806-21	23
492	Prediction of herb-drug metabolic interactions: a simulation study. 2005 , 19, 464-71	17
491	[Drug preparations of calcium channel blockers]. 2005 , 34, 400-10	
490	General principles of pharmacotherapy for the patient with HIV infection. 2005 , 56-87	
489	In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. 2005 , 33, 754-63	51
488	Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. 2005 , 33, 243-53	137
487	Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. 2005 , 111, 230-9	74

486	Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. 2005 , 41, 291-300		85
485	Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. 2005 , 1, 283-93		34
484	Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. 2005 , 33, 892-5		39
483	Pharmacogenomics and acquired long QT syndrome. 2005 , 6, 259-70		36
482	Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. 2005 , 46, 565-8		19
481	Antidepressant drug-drug interaction profile update. 2005 , 6, 323-36		16
480	Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. 2005 , 18, 1799-813		55
479	Metabolism and disposition kinetics of nicotine. 2005 , 57, 79-115		1085
478	Drug bioactivation, covalent binding to target proteins and toxicity relevance. 2005 , 37, 41-213		228
477	[Antihypertensive drug-drug interactions]. 2005 , 124, 782-9		8
476	An overview of psychotropic drug-drug interactions. 2005 , 46, 464-94		98
475	A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. <i>AAPS Journal</i> , 2005 , 7, E6-13	3-7	40
474	Drug interactions of clinical importance with antihyperglycaemic agents: an update. 2005 , 28, 601-31		99
473	Drug treatment of depression in HIV-positive patients : safety considerations. 2005 , 28, 753-62		21
472	The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. 2005 , 28, 789-801		61
471	Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 279-304	6.2	349
470	Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 915-34	6.2	48
469	Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 1035-50	6.2	121

468	Herb-drug interactions: a literature review. 2005 , 65, 1239-82	417
467	Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. 2005 , 48, 5966-79	121
466	Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. 2005 , 23, 443-64	56
465	Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. 2005 , 45, 79-88	25
464	Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model. 2006 , 36, 351-65	12
463	Consider adverse effects and pharmacological interactions when treating depression in HIV-positive patients. 2006 , 22, 9-11	
462	Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments. 2006 , 2, 961-79	9
461	Controversia terapéutica: clopidogrel y estatinas. 2006 , 18, 34-48	
460	Next revolution in the molecular theranostics of infectious diseases: microfabricated systems for personalized medicine. 2006 , 6, 433-50	46
459	Grapefruit-drug interactions: can interactions with drugs be avoided?. 2006 , 46, 1390-416	87
458	Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 855-69	6.2 81
457	Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. 2006 , 2, 875-94	948
456	Specific human CYP 450 isoform metabolism of a pentachlorobiphenyl (PCB-IUPAC# 101). 2006 , 344, 129-33	31
455	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. 2006 , 234, 4-33	190
454	Cytochrome P450 and its role in veterinary drug interactions. 2006 , 36, 975-85, v	27
453	Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats. 2006 , 79, 50-6	12
452	Update on clinically significant drug interactions in dermatology. 2006 , 54, 676-84	9
451	Anesthetic drug interactions. 2006 , 119-127	

450	Clinical oral doses of dexamethasone decreases intrinsic clearance of quinidine, a cytochrome P450 3A substrate in dogs. 2006 , 68, 903-7	6
449	Effect of simultaneous insertion of oleaginous base on the absorption and on the anticonvulsant effect of diazepam suppository. 2006 , 29, 705-8	2
448	Increasing survival with HIV: impact on nursing care. 2006 , 17, 8-17	16
447	Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. 2006 , 10, 736-9	16
446	Selected physiologic compatibilities and incompatibilities between human and porcine organ systems. 2006 , 13, 488-99	146
445	Current understanding of delayed anticonvulsant hypersensitivity reactions. 2006 , 6, 33-7	37
444	Variation in Furanocoumarin Content and New Furanocoumarin Dimers in Commercial Grapefruit (Citrus paradisi Macf.) Juices. 2006 , 70, C307-C312	29
443	One Tangerine/Grapefruit Hybrid (Tangelo) Contains Trace Amounts of Furanocoumarins at a Level Too Low To Be Associated with Grapefruit/Drug Interactions. 2006 , 70, c419-c422	7
442	Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. 2006 , 62, 372-6	30
441	Drug interactions in cancer therapy. 2006 , 6, 546-58	224
440	Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. 2006 , 18, 104-10	67
439	Optimization of sulfonamide derivatives as highly selective EP1 receptor antagonists. 2006 , 14, 7774-89	9
438	A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients. 2006 , 837, 69-75	24
437	Characterization of metabolites and cytochrome P450 isoforms involved in the microsomal metabolism of aconitine. 2006 , 844, 292-300	54
436	Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. 2006 , 62, 721-6	87
435	Use of arterially perfused rabbit ventricular wedge in predicting arrhythmogenic potentials of drugs. 2006 , 54, 261-72	31
434	Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. 2006 , 26, 1730-44	217
433	Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography. 2006 , 20, 28-36	26

432	Liquid chromatographic-electrospray tandem mass spectrometric determination of clarithromycin in human plasma. 2006 , 20, 1242-51	25
431	In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. 2006 , 34, 1546-55	30
430	Antimicrobial-associated QT interval prolongation: points of interest. 2006 , 43, 1603-11	168
429	Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. 2006 , 34, 1875-9	27
428	Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. 2006 , 34, 81-90	75
427	Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. 2006 , 34, 775-82	27
426	Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. 2006 , 22, 240-7	20
425	Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction in vitro. 2006 , 25, 715-21	18
424	Disposition of loratadine in healthy volunteers. 2007 , 37, 753-69	35
423	Effect of Lactobacillus casei on the absorption of nifedipine from rat small intestine. 2007 , 22, 96-102	11
422	Effect of benidipine on simvastatin metabolism in human liver microsomes. 2007 , 22, 199-205	3
421	Chronic sildenafil in men with diabetes and erectile dysfunction. 2007 , 3, 451-64	24
420	The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. 2007 , 35, 1149-56	21
419	Benzodiazepines. 2007 ,	
418	Effects of continuous ingestion of herbal teas on intestinal CYP3A in the rat. 2007 , 103, 214-21	27
417	HIV and AIDS. 474-505	
416	Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. 2007 , 21, 1535-9	6
415	Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. 2007 , 29, 687-710	265

414	Fractionated neem leaf extract is safe and increases CD4+ cell levels in HIV/AIDS patients. 2007 , 14, 369-74		15
413	Effect of subacute methyl parathion administration on the pharmacokinetics and pharmacodynamics of nifedipine in rats. 2007 , 24, 1-4		1
412	A lesson for everyone in drug-drug interactions. 2007 , 118, e19-20		4
411	Application of chimeric mice with humanized liver for predictive ADME. 2007 , 39, 145-57		45
410	Pharmacokinetic interactions with thiazolidinediones. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 1-12	6.2	41
409	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 93-108	6.2	56
408	Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 495-501	6.2	27
407	Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry. 2007 , 20, 1373-8		33
406	Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile. 2007 , 17, 3072-6		42
405	Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. 2007 , 26, 258-68		174
404	Intestinal drug transporter expression and the impact of grapefruit juice in humans. 2007 , 81, 362-70		334
403	Historical review of carbamazepine for the treatment of bipolar disorder. 2007 , 27, 68-88		17
402	Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. 2007 , 37, 389-412		64
401	Optimizing response to phosphodiesterase type 5 inhibitors. 2007 , 4, 1-6		1
400	In vitro inhibitory potential of decursin and decursinol angelate on the catalytic activity of cytochrome P-450 1A1/2, 2D15, and 3A12 isoforms in canine hepatic microsomes. 2008 , 31, 1425-35		14
399	Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. 2008 , 872, 58-62		7
398	Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors. 2008 , 16, 2243-60		13
397	Chimeric mice with humanized liver. 2008 , 246, 9-17		78

396	Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates. <i>AAPS Journal</i> , 2008 , 10, 200-7	3-7	49
395	Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats. 2008 , 29, 1247-52		12
394	Adverse drug interactions in dentistry. 2008 , 46, 109-42		32
393	Polypill: for Pollyanna. 2008 , 3, 92-7		11
392	Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. 2008 , 98, 1797-802		24
391	Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. 2008 , 153, 439-47		67
390	Combination chemical genetics. 2008 , 4, 674-81		142
389	Actual and potential drug interactions associated with methadone. 2008 , 9, 315-44		68
388	Altered pharmacology in the Intensive Care Unit patient. 2008 , 22, 493-501		24
387	Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. 2008 , 38, 521-37		42
386	The hERG potassium channel and hERG screening for drug-induced torsades de pointes. 2008 , 119, 118-32		222
385	Effect of ergot alkaloids associated with fescue toxicosis on hepatic cytochrome P450 and antioxidant proteins. 2008 , 227, 347-56		24
384	Drug metabolism. 2008 , 36, 355-359		5
383	[Serious adverse events derived from the drug interactions of antiretroviral therapy]. 2008 , 208, 557-60		2
382	Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 383-97	6.2	30
381	Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors. 2008 , 51, 3422-36		19
380	Update on erectile dysfunction treatment for aging men. 2008 , 17, 184-189		0
379	Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. 2008 , 327, 288-99		117

- 378 Hypnosedative-induced complex behaviours : incidence, mechanisms and management. **2008**, 22, 1021-36 110
- 377 Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. **2008**, 73, 1029-36 97
- 376 3-amino-7-phthalazinylbenzoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase. **2008**, 51, 6280-92 23
- 375 Pharmacological enhancement of protease inhibitors with ritonavir: an update. **2008**, 1, 533-45 10
- 374 A New Inhaled Corticosteroid: Ciclesonide. **2008**, 21, 149-152
- 373 Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver. **2008**, 38, 239-48 20
- 372 Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. **2008**, 1, 115-27 15
- 371 Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARE Study. **2008**, 22, 7-16 18
- 370 Liver Transplantation. 235-255
- 369 Irreversible Cytochrome P450 Inhibition: Common Substructures and Implications for Drug Development. **2008**, 267-276
- 368 Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults. **2009**, 1, CMT.S1088
- 367 Cytochrome P450: Structure, Function, and Application in Drug Discovery and Development. 55-107
- 366 FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo. **2009**, 106, 1336-41 23
- 365 Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. **2009**, 39, 749-56 8
- 364 Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. **2009**, 23, 224-31 39
- 363 Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. **2009**, 37, 2305-13 54
- 362 Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. **2009**, 69, 8996-9002 78
- 361 Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. **2009**, 14, 891-8 34

360	Metabolic stability and determination of cytochrome P450 isoenzymes contribution to the metabolism of medetomidine in dog liver microsomes. 2010 , 24, 868-77		10
359	Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. 2009 , 35, 603-12		48
358	Design, synthesis, and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors. 2009 , 19, 184-7		32
357	Application of mechanism-based CYP inhibition for predicting drug-drug interactions. 2009 , 5, 579-605		25
356	Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. 2009 , 63, 697-702		20
355	How important is intestinal cytochrome P450 3A metabolism?. 2009 , 30, 223-7		38
354	Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes. <i>Toxicology in Vitro</i> , 2009 , 23, 185-93	3.6	5
353	Cytotoxicity of ginkgolic acid in HepG2 cells and primary rat hepatocytes. 2009 , 187, 131-6		60
352	Predicting the clinical relevance of drug interactions from pre-approval studies. 2009 , 32, 1017-39		14
351	Comparison of inhaled corticosteroids: an update. 2009 , 43, 519-27		77
350	Effects of oral posaconazole on the pharmacokinetics of sirolimus. 2009 , 25, 701-7		42
349	Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. 2009 , 49, 1343-52		48
348	Anaesthetic considerations of the HIV-infected patients. 2009 , 22, 412-8		8
347	Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users. 2010 , 24, 331-40		33
346	Azole antimycotics and drug interactions in the perioperative period. 2010 , 23, 441-8		4
345	Practical Pharmacological Maintenance Treatment of Bipolar Disorder. 2010 , 304-332		
344	Theoretical considerations on quantitative prediction of drug-drug interactions. 2010 , 25, 48-61		20
343	Pharmacokinetic Interaction between Nifedipine and Coenzyme Q10 in Rats: A New Type of Drug-Supplement Interaction. 2010 , 56, 310-320		4

342	Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. 2004 , 56, 477-83	6
341	Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats. 2004 , 56, 1259-66	9
340	Effects of non-steroidal anti-inflammatory drugs on the pharmacokinetics and elimination of aciclovir in rats. 2005 , 57, 393-8	9
339	Use of in vivo animal models to assess pharmacokinetic drug-drug interactions. 2010 , 27, 1772-87	44
338	Management of drug and food interactions with azole antifungal agents in transplant recipients. 2010 , 30, 842-54	97
337	Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. 2010 , 52, 1590-9	29
336	Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. 2010 , 160, 1224-33	57
335	Drug- and non-drug-associated QT interval prolongation. 2010 , 70, 16-23	192
334	Fruit juice inhibition of uptake transport: a new type of food-drug interaction. 2010 , 70, 645-55	164
333	Effects of ciclosporin therapy on xylazine/ketamine anaesthesia in a rat model. 2010 , 33, 100-2	3
332	Significant sirolimus and dronedarone interaction in a kidney transplant recipient. 2010 , 44, 1338-41	10
331	Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 beta-hydroxycortisol/cortisol ratio after grapefruit juice intake in healthy Chinese. 2010 , 50, 775-84	15
330	Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?. 2010 , 50, 1330-8	29
329	Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. 2010 , 45, 1088-94	15
328	Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions. 2010 , 51, 1414-23	23
327	Cardiac Toxicity. 2010 , 287-314	
326	Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. 2010 , 401, 149-53	42
325	Evidence-based management of herb-drug interaction in cancer chemotherapy. 2010 , 6, 324-9	32

324	Effects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice. 2010 , 37, 335-45	12
323	Effects of hepatic drug-metabolizing enzyme induction on clinical pathology parameters in animals and man. 2010 , 38, 810-28	58
322	Potential of an in vitro toolbox combined with exposure data as a first step for the risk assessment of dietary chemical contaminants. 2011 , 28, 1136-58	2
321	Characterization of metabolites and human P450 isoforms involved in the microsomal metabolism of mesaconitine. 2011 , 41, 46-58	29
320	A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. 2011 , 63, 390-410	85
319	QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. 2011 , 120, 103-10	83
318	Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. 2011 , 31, 143-53	33
317	Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. 2011 , 51, 1721-7	39
316	Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. 2011 , 10, 779-93	44
315	IDSite: An accurate approach to predict P450-mediated drug metabolism. 2011 , 7, 3829-3845	38
314	Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. 2011 , 51, 359-67	47
313	Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. 2011 , 202, 47-54	60
312	3,4-methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition. 2011 , 203, 82-91	12
311	Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity. 2011 , 205, 47-54	59
310	Abstracts. 2011 , 43, 30-89	
309	Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. 2011 , 3, 13-25	16
308	PharmGKB summary: carbamazepine pathway. 2011 , 21, 906-10	64
307	Drug Metabolism and Toxicity in Chimeric Mice with Humanized Liver. 2011 , 57, 22-27	5

306	Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. 2011 , 71, 522-7	39
305	Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. 2011 , 75, 585-91	87
304	Cellular localization and functional significance of CYP3A4 in the human epileptic brain. 2011 , 52, 562-71	59
303	Effect of diallyl trisulfide on the pharmacokinetics of nifedipine in rats. 2011 , 76, T30-4	13
302	Effect of maturity, processing, and storage on the furanocoumarin composition of grapefruit and grapefruit juice. 2011 , 76, C543-8	23
301	Drug-drug interactions in HIV medicine: a not so simple and straightforward road to the future. 2011 , 60, 1497-9	2
300	Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking. 2011 , 650, 138-44	37
299	Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China. 2011 , 67, 553-62	5
298	Metabolism of dl-praeruptorin A in rat liver microsomes using HPLC-electrospray ionization tandem mass spectrometry. 2011 , 34, 1311-21	10
297	Effect of diallyl trisulfide on the pharmacokinetics of dipyridamole in rats. 2011 , 34, 1957-64	5
296	Effects of grapefruit, grapefruit juice and water preloads on energy balance, weight loss, body composition, and cardiometabolic risk in free-living obese adults. 2011 , 8, 8	44
295	Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. 2011 , 100, 3854-61	29
294	Factors affecting interindividual differences in clozapine response: a review and case report. 2011 , 26, 177-87	20
293	Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. 2011 , 26, 154-61	27
292	Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. 2011 , 51, 75-83	46
291	Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology. 2011 , 63, 243-67	81
290	Sex differences in drug disposition. 2011 , 2011, 187103	158
289	Effects of powdered whole grapefruit and metoclopramide on the pharmacokinetics of cyclosporine in dogs. 2011 , 72, 687-93	18

288	A mechanistic insight into 3,4-methylenedioxymethamphetamine ("ecstasy")-mediated hepatotoxicity. 2011 , 31, 193-205		22
287	Mechanisms of action of antiepileptic drugs. 2011 , 8, 307-313		14
286	Cytochrome P450-mediated cardiovascular drug interactions. 2011 , 7, 1065-82		21
285	The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. <i>Cmaj</i> , 2011 , 183, 303-7	3.5	53
284	Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers. 2012 , 42, 1128-37		16
283	Evolutionary aspects of animal models. 2012 , 49, 876-8		2
282	Recurrence of panic attacks after brucellosis treatment--highly probable citalopram and rifampin drug interaction. 2012 , 32, 842-4		1
281	Important Antiretroviral Drug Interactions With Benzodiazepines Used for Sedation During Bronchoscopy: Response. 2012 , 141, 1125-1126		
280	Comparison of three fluorescent CYP3A substrates in two vertebrate models: pig and Atlantic salmon. 2012 , 6, 633-40		26
279	Diabetes Mellitus Reduces the Clearance of Atorvastatin Lactone. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 591-606	6.2	16
278	Pharmacodynamic Differential Serum Chromatography for Identifying the Pharmacodynamic Material Basis of a Traditional Chinese Medicine. 2012 , 75, 1129-1134		1
277	hERG K(+) channels: structure, function, and clinical significance. 2012 , 92, 1393-478		426
276	Tissue distribution and cytochrome P450 inhibition of sesaminol and its tetrahydrofuranoid metabolites. 2012 , 60, 8616-23		8
275	Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation. 2012 , 26, E544-8		16
274	Psychotropic drug-drug interactions involving P-glycoprotein. 2012 , 26, 959-73		40
273	Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. 2012 , 34, 2011-9.e1		16
272	Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women. 2012 , 86, 337-44		17
271	Food, pain, and drugs: does it matter what pain patients eat?. 2012 , 153, 1993-1996		29

270	Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not?. 2012 , 64, 1554-9	6
269	Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. 2012 , 70, 823-32	29
268	Reaction Phenotyping. 2012 , 189-212	1
267	Inclusion of human intravenous study data in new drug applications-impact of the Japanese guidance. 2012 , 101, 2557-63	
266	Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme. 2012 , 17, 3407-60	19
265	Quantification of fexofenadine in biological matrices: a review of bioanalytical methods. 2012 , 26, 942-61	
264	Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. 2012 , 95, 564-9	26
263	Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers. 2012 , 34, 1182-94	27
262	PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers. 2013 , 69, 1917-25	14
261	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. 2013 , 9, 1193-205	19
260	Author's Reply to Kotlinska-Lemieszek: "Should Midazolam Drug-Drug Interactions Be of Concern to Palliative Care Physicians?". 2013 , 36, 791-2	1
259	Clinically Relevant Drug-Drug and Drug-Food Interactions. 2013 , 27, 9-23	7
258	Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability. 2013 , 102, 541-55	16
257	Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. 2013 , 75, 507-15	16
256	Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. 2013 , 55, 2125-38	158
255	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens. 2013 , 56, 1974-83	23
254	NADPH P450 oxidoreductase: structure, function, and pathology of diseases. 2013 , 138, 229-54	153
253	Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. 2013 , 31, 381-9	21

252	A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 763-81	6.2	27
251	Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions. 2013 , 3,		14
250	Cytochrome P450 3A4FNx011B as pharmacogenomic predictor of tacrolimus pharmacokinetics and clinical outcome in the liver transplant recipients. 2013 , 19, 89-95		3
249	Safety of midazolam for sedation of HIV-positive patients undergoing colonoscopy. 2013 , 14, 379-84		1
248	Environmental modification. 279-284		
247	Pharmacogenomics and cerebral dysfunction. 305-315		
246	Pharmacogenetic insights into migraine treatment in children. 2014 , 15, 1539-50		12
245	Rhabdomyolysis in an HIV-infected patient following coronary angiography: case report and literature review. 2014 , 25, 452-4		3
244	Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis. 2014 , 174 Suppl 2, 3-12		31
243	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. 2014 , 44, 1364-88		70
242	Tacrolimus dosage requirements in lung transplant recipients receiving antifungal prophylaxis with voriconazole followed by itraconazole: a preliminary prospective study. 2014 , 28, 911-5		5
241	Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. 2014 , 45, 877-86		1
240	Validation of 4βhydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. 2014 , 78, 1122-34		55
239	Urinary diazepam metabolite distribution in a chronic pain population. 2014 , 38, 135-42		14
238	Drug-drug interaction and doping, part 1: an in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of toremifene. 2014 , 6, 482-91		5
237	Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical data. <i>AAPS Journal</i> , 2014 , 16, 1309-20	3-7	24
236	Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. 2014 , 34, 651-9		45
235	Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib. 2014 , 74, 55-61		5

234	The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians. 2014 , 39, 383-9	13
233	Pharmacokinetic interaction studies of fenugreek with CYP3A substrates cyclosporine and carbamazepine. 2014 , 39, 147-53	9
232	Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A. 2014 , 35, 382-90	14
231	Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. 2014 , 13, 179-85	8
230	[Determination of triazolam and midazolam in human plasma using gas chromatography with microelectron capture detection for clinical application]. 2014 , 134, 119-25	
229	Statin-induced rhabdomyolysis: a comprehensive review of case reports. 2014 , 66, 124-32	50
228	Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women. 2014 , 65, 72-7	18
227	General Principles of Pharmacologic Therapy. 2015 , 2025-2040	1
226	Identification and characterization of in vitro and in vivo metabolites of steroidal alkaloid veratramine. 2015 , 36, 308-24	5
225	A Case of Hypotension and Bradycardia Precipitated by Drug Interaction of Clarithromycin and Calcium-Channel Blocker. 2015 , 63, 1966-7	6
224	Interactions between CYP3A4 and Dietary Polyphenols. 2015 , 2015, 854015	94
223	Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. 2015 , 50, 438-43	12
222	Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4. 2015 , 85, 71-8	46
221	A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products. 2015 , 11, 326-41	52
220	Human microsomal cytochrome P450-mediated reduction of oxysophocarpine, an active and highly toxic constituent derived from <i>Sophora flavescens</i> species, and its intestinal absorption and metabolism in rat. 2015 , 105, 26-36	13
219	Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. <i>Cmaj</i> , 2015 , 187, 174-180	3-5 41
218	Intraclass differences among antihypertensive drugs. 2015 , 55, 333-52	9
217	Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. 2015 , 56, 439-49	19

216	Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. 2015 , 79, 278-85	47
215	Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate. 2015 , 40, 389-99	6
214	Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. 2015 , 24, 38-44	47
213	Ivacaftor therapy in siblings with cystic fibrosis-the potential implications of Itraconazole in dosage and efficacy. 2015 , 31, 49-50	5
212	Content evaluation of 4 furanocoumarin monomers in various citrus germplasm. 2015 , 187, 75-81	17
211	Possible drug-drug interaction in dogs and cats resulted from alteration in drug metabolism: A mini review. 2015 , 6, 383-92	10
210	Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. 2015 , 43, 812-8	16
209	Colchicine-clarithromycin-induced rhabdomyolysis in Familial Mediterranean Fever patients under treatment for Helicobacter pylori. 2015 , 35, 1937-41	8
208	Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver. 2015 , 43, 1208-17	21
207	Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants. 2015 , 4, 155-160	33
206	Pharmaco-therapeutic considerations for using colchicine to treat idiopathic pericarditis in the USA. 2015 , 15, 295-306	8
205	Single nucleotide polymorphism of CYP3A4 intron 2 and its influence on CYP3A4 mRNA expression and liver enzymatic activity in human liver. 2015 , 35, 502-507	1
204	Cytochrome P450 isoenzymes in rat and human liver microsomes associate with the metabolism of total coumarins in Fructus Cnidii. 2015 , 40, 373-7	19
203	Acute kidney injury induced by antimicrobial agents in the elderly: awareness and mitigation strategies. 2015 , 32, 1-12	8
202	In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug-drug interactions. 2015 , 232, 458-65	14
201	Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. 2015 , 91, 71-5	9
200	Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. 2015 , 67, 44-51	12
199	[Severe or life-threatening interactions between antiretrovirals and non-HIV drugs]. 2015 , 33, e15-30	6

198	Benzodiazepines. 2016 , 863-877		
197	Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1535-1545	6.2	27
196	An association between systemic cyclosporine administration and development of acute bullous keratopathy in cats. 2016 , 19 Suppl 1, 77-85		7
195	Drug Interactions. 2016 , 265-292		
194	La importancia de la educaci3n sanitaria del paciente con VIH en tratamiento antirretroviral para evitar interacciones medicamentosas. 2016 , 23, 255-256		
193	Drug interaction study of natural steroids from herbs specifically toward human UDP-glucuronosyltransferase (UGT) 1A4 and their quantitative structure activity relationship (QSAR) analysis for prediction. 2016 , 110, 139-150		13
192	Clinically Significant Interactions with Mood Stabilisers. 2016 , 423-449		0
191	Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study. 2016 , 3, 99-105		17
190	Pigs in Toxicology: Breed Differences in Metabolism and Background Findings. 2016 , 44, 575-90		26
189	Clinically and pharmacologically relevant interactions of antidiabetic drugs. 2016 , 7, 69-83		63
188	Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study. 2016 , 95, e2487		28
187	[Herb-drug enzyme-mediated interactions and the associated experimental methods: a review]. 2016 , 36, 392-408		13
186	Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans. 2016 , 37, 3-14		12
185	Travel to High Altitude Following Solid Organ Transplantation. 2016 , 17, 147-156		3
184	Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. 2016 , 1033-1034, 117-127		41
183	Pramipexole in the treatment of REM sleep behaviour disorder: A critical review. 2016 , 243, 365-72		10
182	Metabolism-Based Drug-Drug Interactions in Critically Ill Patients: Clinical Relevance and Predictability of In Vitro Systems. 2016 , 1-48		
181	Potential factors involved in the causation of rhabdomyolysis following status asthmaticus. 2016 , 12, 43		3

180	High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia. 2016 , 82, 504-11		18
179	The rebirth of interest in renal tubular function. 2016 , 310, F1351-5		24
178	Mechanism of Proarrhythmic Effects of Potassium Channel Blockers. 2016 , 8, 395-410		9
177	A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. 2016 , 63, 634-43		28
176	Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats. 2016 , 41, 231-8		9
175	CYP3A activity: towards dose adaptation to the individual. 2016 , 12, 479-97		32
174	Drug Interactions in Neurocritical Care. 2017 , 27, 287-296		1
173	Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. 2017 , 110, 51-61		93
172	Glucuronidation: driving factors and their impact on glucuronide disposition. 2017 , 49, 105-138		41
171	Rifampicin reverses nifedipine effect inducing uncontrolled essential hypertension. 2017 , 31, 587-589		6
170	Targeted Modulation of Macrophage Functionality by Nanotheranostics in Inflammatory Liver Disease and Cancer. 2017 , 213-222		
169	Food, gastrointestinal pH, and models of oral drug absorption. 2017 , 112, 234-248		116
168	Life-threatening drug interactions: what the physician needs to know. 2017 , 47, 501-512		22
167	Drug-induced fatal arrhythmias: Acquired long QT and Brugada syndromes. 2017 , 176, 48-59		21
166	Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions. <i>Molecular Pharmaceutics</i> , 2017 , 14, 1754-1759	5.6	13
165	Rapid screening the potential mechanism-based inhibitors of CYP3A4 from <i>Tripterygium wilfordii</i> based on computer approaches combined with in vitro bioassay. 2017 , 25, 2689-2700		10
164	The New Era of Hepatitis C: Therapy in Liver Transplant Recipients. 2017 , 21, 421-434		5
163	Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. 2017 , 72, 3414-3419		27

162	Functional annotation of chemical libraries across diverse biological processes. 2017 , 13, 982-993	48
161	Enhanced Oral Bioavailability of Diltiazem by the Influence of Gallic Acid and Ellagic Acid in Male Wistar Rats: Involvement of CYP3A and P-gp Inhibition. 2017 , 31, 1441-1448	12
160	Effects of Cilostazol on the Pharmacokinetics of Nifedipine After Oral and Intravenous Administration in Rats. 2017 , 51, 748-755	1
159	Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human. 2017 , 47, 470-478	2
158	Introduction to Clinical Pharmacology. 2017 , 365-388	6
157	Effects of <i>Paederia foetida</i> and its Bioactive Phytochemical Constituent Lupeol on Hepatic Phase I Drug Metabolism. 2017 , 12, 1934578X1701200	
156	Toxicology. 2017 , 603-620	2
155	Amentoflavone is a potent broad-spectrum inhibitor of human UDP-glucuronosyltransferases. 2018 , 284, 48-55	23
154	Carotid ergotism with retinal ischemia. 2018 , 8, 153-155	1
153	Drug-Drug Interactions as a Complication of Maxillofacial Surgery. 2018 , 643-659	
152	Modulation of the interaction between human P450 3A4 and <i>B. megaterium</i> reductase via engineered loops. 2018 , 1866, 116-125	10
151	Therapeutic challenges in the mature patient. 2018 , 36, 128-139	1
150	Chimeric mice with humanized liver: Application in drug metabolism and pharmacokinetics studies for drug discovery. 2018 , 33, 31-39	29
149	Computational Methods for Developing Novel Antiaging Interventions. 2018 , 175-193	7
148	Mechanisms and the clinical relevance of complex drug-drug interactions. 2018 , 10, 123-134	10
147	Pharmacogenetic considerations for migraine therapies. 2018 , 14, 1161-1167	9
146	Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. 2018 , 61, 9889-9907	125
145	Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence. 2018 , 38, S50-S65	50

144	Guidelines for the management of paediatric cholera infection: a systematic review of the evidence. 2018 , 38, S16-S31		10
143	In Vitro Antioxidant Potential and Effect of a Glutathione-Enhancer Dietary Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity. 2018 , 2018, 7462839		6
142	Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors. 2018 , 44, 371-391		11
141	A Systems Biology Approach for Personalized Medicine in Refractory Epilepsy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	11
140	Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis. 2019 , 14, e0220159		16
139	Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection. 2019 , 39, 857-864		2
138	From Petri Dish to Patient: Bioavailability Estimation and Mechanism of Action for Antimicrobial and Immunomodulatory Natural Products. 2019 , 10, 2470		21
137	The future of pharmacogenetics in the treatment of migraine. 2019 , 20, 1159-1173		5
136	The Prediction of the Area under the Curve and Clearance of Midazolam from Single-Point Plasma Concentration and Urinary Excretion in Healthy Volunteers. 2019 , 42, 1590-1595		2
135	Molecular Dynamics Simulation Framework to Probe the Binding Hypothesis of CYP3A4 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	6
134	Safety-Related Quality Issues for the Development of Herbal Drugs. 2019 , 655-683		2
133	The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review. 2019 , 20, 1299-1311		32
132	Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P-glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover. 2019 , 134, 194-204		7
131	Hepatitis C and kidney transplant: The eradication time of the virus has arrived. 2019 , 39, 458-472		3
130	Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies. 2019 , 125, 117-122		1
129	The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group. 2019 , 134, 31-59		119
128	Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in and. 2019 , 47, 425-435		11
127	Principles of Dose, Schedule, and Combination Therapy. 2019 , 1-15		

126	Hepatitis C and kidney transplant: The eradication time of the virus has arrived. 2019 , 39, 458-472	
125	Carboranylanylinoquinazoline EGFR-inhibitors: toward lead-to-candidate stage in the drug-development pipeline. 2019 , 11, 2273-2285	10
124	Understanding the relevance of herb-drug interaction studies with special focus on interplays: a prerequisite for integrative medicine. 2019 , 4, e15	30
123	Drug Bioavailability Enhancing Agents of Natural Origin (Bioenhancers) that Modulate Drug Membrane Permeation and Pre-Systemic Metabolism. 2019 , 11,	32
122	Reproductive toxicity of the hydroethanolic extract of the flowers of and spilanthal in zebrafish: In vivo and in silico evaluation. 2020 , 39, 127-146	9
121	Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. 2020 , 206, 107449	13
120	Regional Differences in Penetration of the Protein Stabilizer Trimethoprim (TMP) in the Rat Central Nervous System. 2020 , 13, 167	
119	Quasi-Irreversible Inhibition of CYP2D6 by Berberine. 2020 , 12,	3
118	ADME/Tox Profiling of Natural Products: A Focus on BIOFACQUIM. 2020 , 5, 16076-16084	43
117	QT interval prolongation and with donepezil, rivastigmine and galantamine. 2020 , 11, 2042098620942416	3
116	Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes. 2020 , 12,	11
115	Risk assessment of the chiral pesticide fenamiphos in a human model: Cytochrome P450 phenotyping and inhibition studies. 2020 , 146, 111826	5
114	A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition. 2020 , 60, 1237-1253	1
113	Pharmacokinetic Parameters of HIV-1 Protease Inhibitors. 2020 , 15, 1018-1029	1
112	Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. 2020 , 64,	2
111	Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatiirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole). 2020 , 60, 1314-1323	3
110	Single-atom nanozymes: A rising star for biosensing and biomedicine. 2020 , 418, 213376	58
109	The Fe-N-C Nanozyme with Both Accelerated and Inhibited Biocatalytic Activities Capable of Accessing Drug-Drug Interactions. 2020 , 132, 14606-14611	11

108	The Fe-N-C Nanozyme with Both Accelerated and Inhibited Biocatalytic Activities Capable of Accessing Drug-Drug Interactions. 2020 , 59, 14498-14503	43
107	Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat. 2021 , 14, 487-491	4
106	Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy. 2021 , 17, 397-412	2
105	Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. 2021 , 893, 173813	14
104	Management of fever and neutropenia in the adult patient with acute myeloid leukemia. 2021 , 19, 359-378	4
103	The ADME Encyclopedia. 2021 , 1-11	
102	Verification of a cocktail approach for quantitative drug-drug interaction assessment: a comparative analysis between the results of a single drug and a cocktail drug. 2021 , 51, 404-412	
101	Medical management of Cushing's disease. 2021 , 231-244	
100	Drug Related Complications After Bariatric Surgery. 2021 , 301-312	
99	Advances in Oral Drug Delivery. 2021 , 12, 618411	69
98	Visual Side Effects Linked to Sildenafil Consumption: An Update. 2021 , 9,	3
97	Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine. 2021 , 12, 651720	3
96	The Use of Bio-Active Compounds of Citrus Fruits as Chemopreventive Agents and Inhibitor of Cancer Cells Viability. 2021 , 21, 1058-1068	0
95	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine. 2021 , 110, 1935-1947	2
94	Changes in the Pharmacokinetics and Pharmacodynamics of Sildenafil in Cigarette and Cannabis Smokers. 2021 , 13,	1
93	Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper. 2021 , 44, 825-834	1
92	Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach. 2021 , 140, 111742	8
91	Clinical Significance and Integrative Analysis of the SMC Family in Hepatocellular Carcinoma. 2021 , 8, 727965	4

90	Nanoparticulate Drug Delivery Strategies to Address Intestinal Cytochrome P450 CYP3A4 Metabolism towards Personalized Medicine. 2021 , 13,	5
89	Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin. <i>AAPS Journal</i> , 2021 , 23, 104	3-7 4
88	Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications. 2021 ,	2
87	One-component nano-metal-organic frameworks with superior multienzyme-mimic activities for 1,4-dihydropyridine metabolism. 2022 , 605, 214-222	2
86	Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: Focus on venlafaxine. 2000 , 12, 30-44	116
85	Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction. 2017 , 37, 1438-1447	16
84	Young at Heart. 2015 , 767-769	1
83	CYP3A4: The Workhorse. 2015 , 37-40	1
82	Antimicrobial Drugs. 2004 , 295-318	1
81	Grapefruit Juice-Drug Interaction Issues. 2004 , 175-194	0
80	HYPNOSEDATIVES. 2009 , 375-450	1
79	Clinical Toxicology. 2012 , 1109-1188	2
78	Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. 2007 , 117, 3583-92	188
77	Case Study. <i>Drugs and the Pharmaceutical Sciences</i> , 2005 , 481-525	1
76	No correlation of hsa-miR-148a with expression of PXR or CYP3A4 in human livers from Chinese Han population. 2013 , 8, e59141	18
75	Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. 2019 , 8, 425-434	3
74	CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. 2014 , 5, 8052-82	81
73	Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. 2005 , 1, 3-13	47

72	Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 591-606	6.2	14
71	Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases. 2011 , 12, 742-9		48
70	Membrane transporter proteins: a challenge for CNS drug development. 2006 , 8, 311-21		83
69	Immunomodulatory Effect of Orally Red Fruit (<i>Pandanus conoideus</i>) Extract on the Expression of CC Chemokine Receptor 5 mRNA in HIV Patients with Antiretroviral Therapy. 2018 , 11, 15-21		10
68	Recognizing and preventing drug interactions in older adults with HIV. 2003 , 29, 5-12		5
67	[Drug interactions and immunosuppression in organ transplant recipients]. 2011 , 131, 2000-3		7
66	Synthesis of new derivatives of aryl-clonazepam via Suzuki Cross-coupling reaction. 2016 , 7, 152-155		1
65	Serotonin-selektive Antidepressiva(SSRI, DSA). 2002 , 223-363		
64	Pharmacology. 2002 , 13-35		
63	Kalziumantagonisten. 2004 , 927-932		
62	DrugDrug Interactions. 2004 ,		
61	Scientific, Mechanistic and Regulatory Issues with Pharmacokinetic Drug-Drug Interactions. <i>Drugs and the Pharmaceutical Sciences</i> , 2004 , 297-343		
60	Designing Experiments for FoodDrug Synergy. 2005 , 413-429		
59	Benzodiazepines. 2006 , 429-443		
58	Pharmacogenetics in Infectious Diseases. 2006 , 155-187		
57	Diabetes, Obesity, and Metabolic Syndrome. <i>Nutrition and Disease Prevention</i> , 2006 , 1-30		
56	Anesthesia and Pain Management in Hand Surgery. 2009 , 947-956		
55	Grapefruit and Other Fruit Juices Interactions with Medicines. 2009 , 267-302		

- 54 Drug Disposition and Drug-Drug Interactions: Importance of First-Pass Metabolism in Gut and Liver. **2010**, 415-435
- 53 Drug interactions medicine. **2010**, 281-308
- 52 Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug-Drug Interactions. 1
- 51 Linkage Between Toxicology of Drugs and Metabolism. 1
- 50 Herbal, food and drug interactions. **2011**, 85-90
- 49 Antimicrobial Drugs. **2012**, 385-411
- 48 CHAPTER 13:Cobicistat and Ritonavir as Pharmacoenhancers for Antiviral Drugs. *RSC Drug Discovery Series*, **2013**, 451-481 0.6
- 47 Identification of Time-Dependent CYP Inhibitors Using Human Liver Microsomes (HLM). *Methods in Pharmacology and Toxicology*, **2014**, 305-314 1.1
- 46 Rhabdomyolysis After the Administration of Clarithromycin in a Japanese Schizophrenic Patient Receiving Aripiprazole: A Possible Impact of CYP2D6 Genotype. *Clinical Neuropsychopharmacology and Therapeutics*, **2014**, 5, 18-22 0.2
- 45 Drug-herb interactions: Mechanisms involved and clinical implications of five commonly and traditionally used herbs. *Tang [humanitas Medicine]*, **2014**, 4, 17.1-17.8 1
- 44 Doggone It! The Case Is Cancelled. **2015**, 393-396
- 43 The Distressed Daughter. **2015**, 385-388
- 42 Cerebral Vasospasm Associated with Clarithromycin-Ergotamine Combination. *Journal of Neurology & Stroke*, **2015**, 2, 0.7
- 41 Cardiovascular Catheterization, Electrophysiology, and Imaging Laboratory Procedures. **2015**, 352-397
- 40 Drug Delivery: Oral Route. 2782-2811
- 39 Iminostilbene Anticonvulsants: Carbamazepine/Oxcarbazepine. **2016**, 1-12
- 38 Iminostilbene Anticonvulsants: Carbamazepine and Oxcarbazepine. **2017**, 1053-1063
- 37 Recent Insights on the Anticancer Properties of Flavonoids: Prospective Candidates for Cancer Chemoprevention and Therapy. **2019**, 425-448

36	Pharmacokinetic Interaction Study for Simvastatin and Parsley and Its Plasma Quantification Using LC-MS: A Focus on Drug Metabolic Enzymes. <i>Iranian Red Crescent Medical Journal</i> , 2019 , In Press,	1.3	
35	Influences of Ferulic Acid on Pharmacokinetics of Carbamazepine in Rats: Possible Mechanism of Herb/food-drug Interactions. <i>International Journal of Pharmacology</i> , 2019 , 15, 978-985	0.7	
34	Inhibitory Effects of Several Fluoroquinolones on Feline CYP1A and 3A in Hepatic Microsomes. <i>Open Journal of Veterinary Medicine</i> , 2020 , 10, 219-237	0.3	2
33	EFEITOS DE POLISSACARDEOS DO JAMBO NO MODELO TUMORAL SOLIDO DE EHRLICH EM CAMUNDONGOS. <i>Infarma: Pharmaceutical Sciences</i> , 2020 , 32, 86-100	0.1	
32	P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. <i>Molecular Pharmaceutics</i> , 2021 , 18, 4371-4384	5.6	0
31	Functional characterization of the chlorzoxazone 6-hydroxylation activity of human cytochrome P450 2E1 allelic variants in Han Chinese. <i>PeerJ</i> , 2020 , 8, e9628	3.1	
30	Risk of stroke, gangrene from ergot drug interactions. <i>Cmaj</i> , 2003 , 168, 1015	3.5	4
29	Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity. <i>Experimental and Clinical Cardiology</i> , 2003 , 8, 99-107		6
28	Drug interactions: a primer for the gastroenterologist. <i>Gastroenterology and Hepatology</i> , 2012 , 8, 376-830.7		4
27	An Investigation into the Role of P-Glycoprotein in the Intestinal Absorption of Repaglinide: Assessed by Everted Gut Sac and Caco-2 Cell Line. <i>Iranian Journal of Pharmaceutical Research</i> , 2019 , 18, 102-110	1.1	4
26	Risk assessment of the inhibition of hydroxygenkwanin on human and rat cytochrome P450 by cocktail method. <i>Toxicology in Vitro</i> , 2021 , 105281	3.6	0
25	Computational identification of potential inhibitory compounds in Indian medicinal and aromatic plant species against major pathogenicity determinants of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021 , 1-19	3.6	2
24	Food-drug interactions and their implications on oral drug bioavailability. 2022 , 263-289		
23	Peripheral limb ischemia- A rare side effect of ergometrine. <i>Indian Journal of Obstetrics and Gynecology Research</i> , 2022 , 9, 111-113	0.6	
22	Potential Drug-Drug Interactions Between Anti-Cancer Drugs and Other Medications in Lung Cancer Patients: A Retrospective Study.. <i>Current Drug Safety</i> , 2022 ,	1.4	
21	Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation. <i>AAPS Journal</i> , 2021 , 24, 12	3.7	1
20	Population-based signals of benzodiazepine drug interactions associated with unintentional traumatic injury.. <i>Journal of Psychiatric Research</i> , 2022 , 151, 299-303	5.2	
19	Resistance and Other Factors Involved in Therapy Failure. <i>Antiviral Therapy</i> , 2001 , 6, 21-27	1.6	28

18	Combination of Protease Inhibitors for the Treatment of HIV-1-Infected Patients: A Review of Pharmacokinetics and Clinical Experience. <i>Antiviral Therapy</i> , 2002 , 6, 201-229	1.6	40
17	Management of Dyslipidaemia in HIV-Infected Patients Receiving Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2004 , 9, 649-663	1.6	8
16	Preparation of Novel Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine Sulfonamides and Their Experimental and Computational Biological Studies. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5892	6.3	3
15	Metabolism Drug Interactions. 2022 , 631-641		
14	A multidimensional metabolomics workflow to image biodistribution and evaluate pharmacodynamics in adult zebrafish. 2022 , 15,		0
13	Important Drug-Drug Interactions for the Addiction Psychiatrist. 2022 ,		
12	Hepatic, Extrahepatic and Extracellular Vesicle Cytochrome P450 2E1 in Alcohol and Acetaminophen-Mediated Adverse Interactions and Potential Treatment Options. 2022 , 11, 2620		0
11	Alprazolam-related deaths in Scotland, 2004-2020. 026988112211040		0
10	Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.		0
9	Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite.		0
8	Principles of Dose, Schedule, and Combination Therapy. 1-13		0
7	Changes in Alprazolam Metabolism by CYP3A4 Mutants. 2022 , 10, 3022		1
6	Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug-drug interactions.		0
5	What Is Known about Midazolam? A Bibliometric Approach of the Literature. 2023 , 11, 96		0
4	Non-Cardiac Medications Induced QT Prolongation in Cardiac patients: A Retrospective Analysis. 2022 , 15, 2107-2113		0
3	Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4. 2023 , 62, 3305-3320		0
2	Synthesis and biological evaluation of coumarin derivatives as selective CYP2A6 inhibitors. 2023 , 86, 129206		0
1	Relationship between clock gene expression and CYP2C19 and CYP3A4 with benzodiazepines. 2023 , 42, 096032712311716		0

